Polymorphic forms of ivabradine hydrochloride

Patent metadata

Field	Value
Publication number	US-9840469-B2
Application number	US-201715485409-A
Country	US
Kind code	B2
Filing date	Apr 12, 2017
Priority date	Nov 14, 2011
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.

First claim

We claim:

1. A crystalline Form II of ivabradine hydrochloride characterized by x-ray powder diffraction having characteristic peaks at about 15.50°, 18.02°, 19.00°, 19.80°, 22.42°, 24.16°, and 25.46°±0.2° (2θ), substantially free from one or more of: (S)-1-(4,5-dimethoxy-1,2-dihydrocyclobutanbenzene-1-yl)-N-methylmethamine (S-methylamine); 7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepine-2-one (tetrahydrobenzazepine); (1S)-4,5-dimethoxy-1-(methylaminomethyl)benzocyclobutane hydrochloride (BCP condense); or (1S)-4,5-dimethoxy-1,2-dihydrocyclobutanebenzen-1-yl)-N-((4,5-dimethoxy-1,2-dihydrocyclobutanebenzen-1-yl)methyl-N-methyl-methamine (dimer impurity), as measured by area percentage of HPLC.

2. The crystalline ivabradine hydrochloride according to claim 1 , wherein single individual impurity is not more than 0.15%, as measured by area percentage of HPLC.

3. The crystalline ivabradine hydrochloride according to claim 1 , wherein the total impurities is not more than 0.15%, as measured by area percentage of HPLC.

4. The crystalline ivabradine hydrochloride according to claim 1 , having a purity of about 99% or more, as measured by area percentage of HPLC.

5. The crystalline ivabradine hydrochloride according to claim 1 , which is substantially free from known crystalline forms β, δ, γ, or amorphous forms after storage for 6 months at 40° C. and a relative humidity of 75% or at 25° C. and a relative humidity of 60%.

6. The crystalline ivabradine hydrochloride according to claim 1 , which is having particle size distributions wherein the 10th volume percentile particle size (D10) is less than about 50 μm, the 50th volume percentile particle size (D50) is less than about 200 μm, or the 90 th volume percentile particle size (D90) is less than about 400 μm, or any combination thereof.

7. The crystalline ivabradine hydrochloride according to claim 5 , comprising a packaging which includes placing crystalline ivabradine hydrochloride under nitrogen atmosphere in a non-permeable bag or placing crystalline ivabradine hydrochloride in polyethylene bag, optionally containing oxygen busters and sealing it or placing crystalline ivabradine hydrochloride in a triple laminated bag, optionally containing oxygen busters and sealing it or placing crystalline ivabradine hydrochloride in triple laminated bag inside a high density polyethylene (HDPE) container.

8. A pharmaceutical composition comprising crystalline Form II of ivabradine hydrochloride characterized by x-ray powder diffraction having characteristic peaks at about 15.50°, 18.02°, 19.00°, 19.80°, 22.42°, 24.16°, and 25.46°±0.2° (2θ)having purity of about 99% or more and substantially free from one or more of: (S)-1-(4,5-dimethoxy-1,2-dihydrocyclobutanbenzene-1-yl)-N-methylmethamine (S-methylamine); 7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepine-2-one (tetrahydrobenzazepine); (1S)-4,5-dimethoxy-1-(methylaminomethyl)benzocyclobutane hydrochloride (BCP condense); or (1S)-4,5-dimethoxy-1,2-dihydrocyclobutanebenzen-1-yl)-N-((4,5-dimethoxy-1,2-dihydrocyclobutane-benzen-1-yl)methyl-N-methyl-methamine (dimer impurity), as measured by area percentage of HPLC.

9. The pharmaceutical composition according to claim 8 , wherein the crystalline ivabradine hydrochloride is crystalline Form II characterized by x-ray powder diffraction having characteristic peaks at about 15.50°, 18.02°, 19.00°, 19.80°, 22.42°, 24.16°, and 25.46°±0.2° (2θ).

10. The crystalline ivabradine hydrochloride according to claim 1 , is prepared by the process comprising:
(a) providing a solution of ivabradine hydrochloride in one or more solvents by heating at about 30° C. to about 120° C.;
(b) obtaining the crystalline Form II of ivabradine hydrochloride by the removal of the solvents; and
(c) drying the crystalline Form II of ivabradine hydrochloride at about 40° C. to about 70° C., wherein the solvent is at least one member selected from the group consisting of methanol, ethanol, isopropanol, butanol, dimethylformamide, dimethylacetamide, dimethylsulfoxide, N-methylpyrrolidone, methyl ethyl ketone, acetone, methyl isobutyl ketone, ethyl acetate, butyl acetate, isopropyl acetate, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, water and mixtures thereof.

11. The process according to claim 10 , wherein the removal of the solvent comprises one or more of filtration, filtration under vacuum, decantation, centrifugation, distillation and distillation under vacuum.

12. A process for preparing crystalline ivabradine hydrochloride according to claim 1 , the process comprising:
(a) contacting ivabradine base with hydrogen chloride in one or more first solvents to obtain ivabradine hydrochloride;
(b) obtaining a solution of ivabradine hydrochloride in one or more second solvents;
(c) optionally adding water to the solution, heating the solution and cooling to obtain the ivabradine hydrochloride wet-cake; and
(d) treating the wet-cake with one or more of first solvents to obtain the crystalline of ivabradine hydrochloride.

13. The process according to claim 12 , wherein the first is at least one member selected from the group consisting of methanol, ethanol, isopropanol, butanol, dimethylformamide, dimethyl acetamide, dimethylsulfoxide, N-methylpyrrolidone, methyl ethyl ketone, acetone, methyl isobutyl ketone, ethyl acetate, butyl acetate, isopropyl acetate, acetonitrile, tetrahydrofuran, 2-methyl tetrahydrofuran, 1,4-dioxane, water, or mixtures thereof.

14. The process according to claim 12 , wherein the second solvent comprises one or more of dimethylformamide, dimethylacetamide, dimethylsulfoxide, N-methylpyrrolidone, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, water, or mixtures thereof.

15. A pharmaceutical composition comprising a crystalline ivabradine hydrochloride according to claim 1 having one or more pharmaceutically acceptable carriers, excipients, or diluents.

16. The pharmaceutical composition according to claim 8 having one or more pharmaceutically acceptable carriers, excipients, or diluents.

Assignees

• Cadila Healthcare Ltd

Inventors

• Dwivedi Shriprakash Dhar
• Prasad Ashok
• Sharma Mukul Hariprasad
• Sharma Piyush Rajendra
• Parihar Jayprakash Ajitsingh

Classifications

• B65B31/00

  Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers · CPC title

• C07D223/16 Primary

  Benzazepines; Hydrogenated benzazepines · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• Y10T428/2982

  Particulate matter [e.g., sphere, flake, etc.] · CPC title

• B65B7/02

  Closing containers or receptacles deformed by, or taking-up shape, of, contents, e.g. bags, sacks · CPC title